MAM
KZR

Meeder Asset Management’s Kezar Life Sciences KZR Stock Holding History

Meeder Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-601
Closed -$53K – 1788
2021
Q3 		$53K Buy
+601
New +$39.8K ﹤0.01% 1070
2020
Q4 		– Sell
-17
Closed – – 2050
2020
Q3 		$0 Hold
17
– – ﹤0.01% 2281
2020
Q2 		$0 Sell
17
-75
-82% -$3.78K ﹤0.01% 2267
2020
Q1 		$3K Buy
92
+11
+14% +$447 ﹤0.01% 1961
2019
Q4 		$3K Buy
81
+4
+5% +$123 ﹤0.01% 1926
2019
Q3 		$3K Buy
+77
New +$3.72K ﹤0.01% 1881

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Meeder Asset Management's KZR Position: Q4 2021 in Review

Meeder Asset Management sold out of Kezar Life Sciences (KZR) in Q4 2021, closing a stake of 601 shares — an estimated $53K sold.

Meeder Asset Management first reported a position in KZR in Q3 2019 and held it in 6 quarters. The position peaked at $53K in Q3 2021. 107 funds tracked by Wall St. Rank hold KZR as of Q4 2021.

  • Meeder Asset Management reported no remaining Kezar Life Sciences position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 601 Kezar Life Sciences shares in Q4 2021, an estimated $53K.
  • Meeder Asset Management first reported a position in Kezar Life Sciences in Q3 2019 and held it in 6 quarters.
  • Meeder Asset Management's Kezar Life Sciences position peaked at $53K in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.